Ranbaxy purchases Senetek's autoinjector rights and assets
Senetek PLC announced the sale to Ranbaxy Pharmaceuticals Inc. of Senetek's patents, trademarks and automated manufacturing equipment for its proprietary disposable autoinjector for self-administration of parenteral drugs, including epinephrine for emergency treatment of anaphylactic shock from peanut and other allergies.
The agreement provides for a non-refundable payment on signing and milestone payments based on regulatory approvals and cumulative sales milestones. Terms also include a percentage of Ranbaxy's and/or its licensees' quarterly net sales of the product(s). Initially, Ranbaxy will focus on pre-filling the autoinjector device with epinephrine. Ranbaxy will also evaluate the development of other parenteral drugs.
Ranbaxy will be making infrastructure investments, including building out the required clean room suites at its facility in New Brunswick, New Jersey to house the highly automated Reliaject production line. Under the agreement, Ranbaxy will be obtaining regulatory approvals and marketing the product. Ranbaxy has also agreed to negotiate with Senetek's licensees for Invicorp for contract manufacturing agreements to produce the autoinjector pre-filled with Invicorp.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Newly found DNA catalysts cleave DNA with water molecule
Dow and greenovation will collaborate on glycosylation research for transgenic plant systems
Urine analysis enables cardiovascular risk assessment

Brain stimulation could help treat Alzheimer’s disease - Study discovers brain network that alleviates symptoms when stimulated
Sartorius reviews fiscal 2008 - Different outlook for the two Group divisions
Sanofi licenses worldwide rights on regenerative treatment for osteoarthritis and cartilage disorders from Scil Technology
Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science
LUX biotechnology wins the Pfizer Award for Innovation
Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research

And the winner is …. cancer research
Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea
